ADC payload development and manufacturing services
Antibody-drug conjugates (ADCs) act by directly targeting and then killing selected cells, affecting both the growth and behavior of cells. They are typically used to treat unwanted malignancies and tumors but are also being developed for use in a number of other therapeutic areas. They represent one of the fastest growing segments of the pharmaceutical and biotechnology industry.
While ADCs have widespread treatment potential, the successful and safe manufacturing of these highly potent drugs requires a highly skilled team of experts and well-controlled manufacturing facilities. ADCs consist of three parts: an antibody specific to the target associated antigen, a payload designed to kill target cancer cells, and a chemical linker to attach the payload to the antibody.
We have leading capabilities and expertise in development across the ADC components: antibodies, payloads, bioconjugation and sterile fill/finish. This integrated capability for the development and manufacture of ADC products can accelerate program timelines and reduce program complexity, resource requirements and risk.